Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lumasiran (ALN-G01), a siRNA product, inhibits hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes this enzyme and thereby prevents the synthesis of oxalate, the toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 813.00 | |
5 mg | Inquiry | $ 1,990.00 | |
10 mg | Inquiry | $ 3,230.00 |
Description | Lumasiran (ALN-G01), a siRNA product, inhibits hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes this enzyme and thereby prevents the synthesis of oxalate, the toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran effectively decreased the excretion of urinary oxalate, which is responsible for the progression of kidney failure in patients with Primary Hyperoxaluria Type 1 (PH1)[1]. |
In vivo | Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. |
Synonyms | ALN-G01 |
Molecular Weight | N/A |
CAS No. | 1834610-13-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lumasiran 1834610-13-7 ALN-G01 inhibitor inhibit